Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin Prophylaxis in Outpatients With MDS and AML
NCT07528417Phase 2Not yet recruiting
- Sponsor
- University of Manitoba
- Start
- Sep 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of levofloxacin in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by University of Manitoba. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
levofloxacin
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07528417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07528417.